Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.930
-0.130 (-12.25%)
At close: Apr 28, 2026, 4:00 PM EDT
0.916
-0.014 (-1.51%)
After-hours: Apr 28, 2026, 7:34 PM EDT
Company Description
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
Skye Bioscience, Inc. is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer and Director |
| Tu Diep M.Sc. | Chief Operating Officer |
| John P. Sharp CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 6, 2026 | PREM14A | Filing |
| Apr 6, 2026 | 8-K/A | [Amend] Current report |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 8-K | Current Report |